Centrosome hyperampli®cation and the consequential mitotic defects contribute to chromosome instability in cancers. Loss or mutational inactivation of p53 has been shown to induce chromosome instability through centrosome hyperampli®cation. It has recently been found that Cdk2-cyclin E is involved in the initiation of centrosome duplication, and that constitutive activation of Cdk2-cyclin E results in the uncoupling of the centrosome duplication cycle and the DNA replication cycle. Cyclin E overexpression and p53 mutations occur frequently in tumors. Here, we show that cyclin E overexpression and loss of p53 synergistically increase the frequency of centrosome hyperampli®cation in cultured cells as well as in tumors developed in p53-null, heterozygous, and wildtype mice. Through examination of cells derived from Waf1-null mice, we further found that Waf1, a potent inhibitor of Cdk2-cyclin E and a major target of p53's transactivation function, is involved in coordinating the initiation of centrosome duplication and DNA replication, suggesting that Waf1 may act as a molecular link between p53 and Cdk2-cyclin E in the control of the centrosome duplication cycle.
Introduction
The centrosome, a major microtubule organizing center of the animal cells, plays vital roles during mitosis as spindle poles, where they are involved in establishing spindle bipolarity, assembling spindle microtubules, and determining the plane where the cleavage furrow is introduced, all of which are essential for accurate chromosome segregation during mitosis (reviewed by Brinkley, 1985; Bornens, 1992; Lange and Gull, 1996) . Since each daughter cell inherits one centrosome, the centrosome must duplicate prior to the subsequent mitosis, and do so only once in each cell cycle. In somatic cells, the centriole, the core component of the centrosome in mammalian cells, initiates duplication near the G1/S boundary of the cell cycle, and centrosome duplication is completed in the G2-phase (reviewed in Mazia, 1987; Vandre and Borisy, 1989; Tournier and Bornens, 1994) . Thus, the centrosome duplication cycle proceeds in a precise coordination with other cell cycle events, including DNA replication. Another major regulation in the centrosome duplication cycle is to suppress re-duplication of centrosomes, once they are duplicated. Abrogation of these regulatory mechanisms results in abnormal ampli®ca-tion of centrosomes. It has previously been shown that the p53 tumor suppressor protein is involved in the regulation of the centrosome duplication cycle, and that loss or mutational inactivation of p53 results in abnormal ampli®cation of centrosomes (Fukasawa et al., 1996 . For example, controls on both initiation of centrosome duplication and suppression of re-duplication are abrogated in embryonic ®bro-blasts derived from p537/7 mice (p537/7 MEFs), resulting in centrosome hyperampli®cation. In these cells, initiation of centrosome duplication occurs much earlier than entry into S phase, and centrosomes undergo multiple cycles of duplication in a single cell (Fukasawa et al., 1996) . The consequences of such defects is most prominently seen in mitosis as multipolar spindles and karyotypic abnormality. Examination of human cancers has shown that centrosome hyperampli®cation is common, and is one of the major causes of chromosome instability (Pihan et al., 1998; Weber et al., 1998; Carroll et al., 1999) , especially in association with mutational inactivation of p53 (Carroll et al., 1999) .
A family of serine/threonine kinases known as cyclin-dependent kinases (Cdks) controls the onset of major cell cycle events such as DNA synthesis and mitosis (reviewed in Nurse, 1994; Sherr, 1994; Heichman and Roberts, 1994; Reed, 1997; Morgan, 1997) . The activity of Cdks is regulated by their association with dierent cyclins, which are temporally expressed at speci®c cell cycle stages. For example, expression of cyclin E, which associates with Cdk2, is maximal in late G1 (Ko et al., 1992; Dulic et al., 1992) , and the formation of active Cdk2-cyclin E complexes is essential for S phase entry (van der Heuvel and Harlow, 1993; Ohtsubo et al., 1993 Ohtsubo et al., , 1995 . For instance, microinjection of anti-cyclin E antibodies inhibits entry into S phase (Ohtsubo and Roberts, 1993) , while overexpression of cyclin E accelerates the G1-S transition (Ohtsubo and Roberts, 1993; Resnitzky et al., 1994; Wimmel et al., 1994) . The levels of cyclin A, which also binds to and activates Cdk2 (reviewed in Heichman and Roberts, 1994; Reed, 1997; Morgan, 1997) are low in late G1 (Marraccino et al., 1992; Carbonaro-Hall et al., 1993) , but increase during S and G2 phases (Ko et al., 1992; Pagano et al., 1992) . Inactivation of cyclin A by microinjection of antibodies causes a failure to replicate DNA, implicating Cdk2-cyclin A in S phase entry and/or S phase progression (Girard et al., 1991) . We and others have recently shown that Cdk2-cyclin E is essential in initiating centrosome duplication (Matsumoto et al., 1999; Lacey et al., 1999; Hinchclie et al., 1999; Tarapore et al., submitted) . A requirement for Cdk2-cyclin A in centrosome duplication has also been reported (Meraldi et al., 1999) . Since activation of Cdk2 is essential for initiating DNA replication, it is reasonable to postulate that activation of Cdk2 by cyclin E (and cyclin A) is a key event in coordinating the initiation of centrosome duplication and DNA replication. In higher eukaryotic cells, activation of Cdk2 is regulated not only by temporal expression of cyclins, but also by a variety of Cdk inhibitors (reviewed by Sherr and Roberts, 1995) . For example, p21
Waf1,Cip1,Sdi1 (Waf1), which was initially identi®ed as a product of a gene transcriptionally up-regulated by p53 (El-Deiry et al., 1993) , as well as a protein interacting with Cdks (Harper et al., 1993; Xiong et al., 1993) , binds to and inhibits the Cdk-cyclin complexes which are active during G1 and S phases, including Cdk4-cyclin D, Cdk2-cyclin E and Cdk2-cyclin A (Harper, 1993; Xiong et al., 1993; Gu et al., 1993) .
Constitutive activation of Cdk2-cyclin E in cells (by ectopic expression of cyclin E) results in loss of coordination between initiation of centrosome duplication and DNA replication. In these cells, centrosomes duplicate rapidly following mitogenic stimulation, much before the onset of DNA synthesis (Tarapore et al., submitted). These ®ndings demonstrate that the initiation of centrosome duplication primarily depends on activation of Cdk2-cyclin E, while the initiation of DNA replication requires additional events before being triggered by Cdk2-cyclin E. The abrogation of this coordination contributes to abnormal ampli®cation of centrosomes, since Swiss 3T3 cells (retaining wildtype p53) overexpressing exogenously transfected cyclin E show a minor, but detectable increase in the frequency of centrosome hyperampli®cation (Tarapore et al., submitted). It has previously been shown that cyclin E overexpression (and constitutive activation of Cdk2-cyclin E) is common in human cancers (reviewed by Keyomarsi and Herliczek, 1997) . p53 is also frequently mutated (Hollstein et al., 1991; , and centrosome hyperampli®cation associated with mutational inactivation of p53 is one of the major causes of chromosome instability in human cancers (Carroll et al., 1999) . In this study, we examined how loss of p53 and cyclin E overexpression together aect the centrosome homeostasis. Through examination of MEFs derived from p53-null mice and Waf1-null mice (as well as wild-type littermates) which overexpress exogenously transfected cyclin E, we found that cyclin E overexpression exacerbated centrosome hyperampli®cation associated with loss of p53. This ®nding was extended to a series of spontaneously formed tumors in p53-null, heterozygous, and wild-type mice. We found that concomitant occurrence of mutational inactivation of p53 and cyclin E overexpression is strongly correlated with a higher degree of centrosome abnormality in these tumors. In addition, our results suggest that Waf1 may be a downstream eector of p53 in the regulatory mechanism that ensures the correct timing of initiation of centrosome duplication (hence coordination of centrosome duplication and DNA replication initiation), but may play only a minor role in the suppression of re-duplication.
Results
Generation of cyclin E overexpressing MEFs derived from p53-null mice, Waf1-null mice, and corresponding wildtype littermates
To test how loss of p53 and cyclin E overexpression (constitutive activation of Cdk2-cyclin E) aects centrosome homeostasis, we ®rst generated cyclin E-overexpressing embryonic ®broblasts (MEFs) derived from p53-null (p537/7) mice and wild-type (p53+/+) littermates, as well as those derived from Waf1-null (Waf17/7) mice and their wild-type (Waf1+/+) littermates. Cells were transfected with a plasmid encoding cyclin E hu together with a plasmid encoding a hygromycin-resistance gene (pHEBO-hyg) at 30 : 1 molar ratio. As a control, an empty plasmid was transfected with pHEBO-hyg. The hygromycin-resistant colonies that had arisen from cyclin E hu -transfected p537/7, p53+/+, Waf17/7 and Waf1+/+ MEFs [p537/7 (CycE), p53+/+(CycE), Waf17/7(CycE), and Waf1+/+ (CycE) respectively] as well as the control vector-transfected cells [p537/7(Vec), p53+/+(Vec), Waf17/7(Vec), and Waf1+/+(Vec), respectively] were pooled, and examined for the expression of cyclin E hu by immunoblot analysis using antibody speci®c to human cyclin E ( Figure 1a) . All of the pooled cells transfected with cyclin E expressed cyclin E hu . Immunocytochemical analysis using anti-human cyclin E antibody showed that 490% of the pooled cyclin E hu -transfected cells were positive for human cyclin E immunostaining (data not shown).
It has previously been shown that cyclin E hu overexpression in mouse or rat cells results in constitutive activation of Cdk2-cyclin E (Ohtsubo et al., 1995; Sgambato et al., 1997; Tarapore et al., submitted) . We examined the level of Cdk2-cyclin E activity in the cyclin E-transfected cells. The lysates were prepared from exponentially growing cells, and subjected to immunoprecipitation using antibodies against mouse and human cyclin E. The immunoprecipitates were then analysed by in vitro kinase reactions using histone H1 as a substrate ( Figure 1b) . All of the cyclin E-transfectants showed high levels of Cdk2-cyclin E activities. In addition, we also tested histone H1 kinase activities of the anti-cyclin E immunoprecipitates from cells at speci®c stages; serum-starved cells that were serum-stimulated for 3 h (early G1), and aphidicolin-treated cells that were released from aphidicolin-block for 6 h (S/G2). The Cdk2-cyclin E complexes immunoprecipitated from these cells showed high levels of histone H1 kinase activities (data not shown). This is consistent with our previous studies, in which cyclin E-overexpression in Swiss 3T3 cells results in constitutive activation of Cdk2-cyclin E throughout the cell cycle (Tarapore et al., submitted). The MEFs used in this study were post-crisis cells, and p53 mutations are known to be frequently associated with cellular immortalization (Harvey and . Thus, we examined the p53 status in p53+/+, Waf17/7 and Waf1+/+ MEFs transfected with either a cyclin E plasmid or a control vector. Cells were ®rst examined by immunoprecipitating p53 from metabolically labeled cells using two conformation-dependent anti-p53 antibodies; Pab246 that reacts with the wild-type conformation of p53, and Pab240 that reacts with the mutant conformation (Yewdell et al., 1986; Gannon et al., 1990; . The p537/7 cell line ectopically expressing the p53 val135 temperature-sensitive mutant product (LTRcG) (Fukasawa and Vande Woude, 1999 ) was included as a control. As previously shown (Martinez et al., 1991) , *60% of p53 val135 were wild-type (Pab246-reactive) and *40% were mutant (Pab240-reactive) in conformation at 378C (Figure 2a ). p53 proteins in p53+/+, Waf17/7 and Waf1+/+ MEFs transfected with either a cyclin E plasmid or an empty vector were detected by Pab246, but not by Pab240 (Figure 2a) .
It has been shown that wild-type p53, but not mutant p53, transcriptionally activates the expression of Waf1 in response to genotoxic drugs such as actinomycin D (Hickman et al., 1997) . We thus examined the inducibility of Waf1 in these cells (except for Waf17/7 cells) in response to actinomycin Dtreatment. Cells in duplicate cultures were incubated in the presence and absence of actinomycin D for 24 h. The lysates were prepared and analysed by immunoblot using anti-Waf1 antibody. The control p537/7(vec) and p537/7(CycE) cells showed no increase in Waf1 expression after actinomycin Dtreatment. In contrast, p53+/+(CycE), p53+/+ (Vec), Waf1+/+ (CycE) and Waf1+/+(Vec) cells showed a substantial increase in Waf1 expression in response to actinomycin D-treatment (Figure 2b ), indicating that these cells contain transcriptionally functional p53.
Thus, we concluded that p53+/+(CycE), p53+/+ (Vec), Waf1+/+(CycE) and Waf1+/+(Vec) cells retained wild-type p53. Waf17/7 MEFs have been shown to continually proliferate in culture (Deng et al., 1995) , and thus it is unlikely that p53 mutations become a selection target in these cells in prolonged culture. Together with the results from immunoprecipitation studies using wild-type/mutant conformationspeci®c antibodies, it is reasonable to conclude that Waf17/7(CycE) and Waf17/7(Vec) cells also retain wild-type p53.
Cyclin E overexpression in p537/7 cells exacerbates abnormal amplification of centrosomes
The p537/7(CycE) and p53+/+(CycE) as well as Waf17/7(CycE) and Waf1+/+(CycE) cells and the corresponding control vector-transfected cells were ®rst examined for their growth properties by¯ow cytometric analysis and BrdU-incorporation assay (Table  1) . Previously, it has been shown that the overexpression of cyclin E results in shortening of G1 phase (Ohtsubo and Roberts, 1993 ; Resnitzky et al., Figure 1 Characterization of cyclin E-transfected p53+/+, p537/7, Waf+/+, and Waf17/7 MEFs. MEFs prepared from p53-null mice and Waf1-null mice as well as wild-type littermates were transfected with a plasmid encoding cyclin E hu together with a plasmid encoding a hygromycin-resistance gene. The drug-resistant colonies were pooled, and designated as p53+/+(CycE), p537/7(CycE), Waf1+/+(CycE), and Waf17/7(CycE) respectively. As controls, cells were also transfected with an empty vector, and designated as p53+/+(Vec), p537/7(Vec), Waf1+/+(Vec), and Waf17/7(Vec) respectively. (a) The lysates prepared from these cells were examined for cyclin E hu expression by immunoblot analysis using anti-human cyclin E polyclonal antibody (C-19, Santa Cruz, CA, USA). NS indicates non-speci®cally recognized proteins. (b) Cdk2-cyclin E activities of cells described in (a) were tested by an in vitro kinase assay (histone H1 as a substrate) of the immunoprecipitates using anti-mouse and human cyclin E polyclonal antibodies (C-19 and M-20, Santa Cruz, CA, USA) as described previously (Fukasawa et al., 1993) 1994; Wimmel et al., 1994) . For instance, in Swiss 3T3 cells G1 phase (*12 h) is shortened to *9 h (Tarapore et al., submitted). Consistent with these studies, cyclin E overexpression resulted in a small, but detectable increase in S phase population with a concomitant decrease in G1 phase population in all cell types except for Waf17/7 cells (Table 1) . A BrdU incorporation assay con®rmed these results: during the BrdU-labeling period (2 h), more cells were in S phase in cyclin Eoverexpressing cells (p537/7 and p53+/+ cells as well as Waf1+/+ cells) than in vector-transfected cells (Table 1) . We did not detect any signi®cant changes in the cell cycle phase distribution patterns and the number of BrdU-incorporated cells in the BrdUincorporation assay between Waf17/7(CycE) and Waf17/7(Vec) cells. This may re¯ect Waf1's positive cell cycle regulatory function, in which Waf1 is necessary for assembly and nuclear transport of Cdk4-cyclin D (Zhang et al., 1994; LaBaer et al., 1997; Cheng et al., 1999) , another G1 kinase complex required for the initiation of DNA replication (reviewed in Sherr, 1994; Sherr and Roberts, 1995) .
Cells were then examined for centrosomes by immunostaining using antibody against g-tubulin.
The g-tubulin is one of major constituents of centrosomes, and immunostaining of g-tubulin detects centrosomes in all phases of the cell cycle (Zheng et al., 1991; Stearns et al., 1991; Joshi et al., 1992) . Cells were also counter-stained with DAPI for visualization of nuclei. The results are shown in Figure 3 , and representative stainings are shown in Figure 4 (panels a ± c and a' ± c'). As previously described (Fukasawa et al., 1996) , p537/7(Vec) cells show extensive centrosome hyperampli®cation; *25% of cells contain abnormal number of centrosomes (n53). In contrast, *1% of p53+/+(Vec) cells contained an abnormal number of centrosomes. These observations con®rm that p53 is involved in the regulation of the centrosome duplication cycle, and that loss of p53 results in abnormal ampli®cation of centrosomes. In p53+/+(Vec) cells, *64% of the cells had one centrosome, and *35% had two centrosomes. This agrees with the cell cycle phase distribution of these cells shown in Table 1 , in which *62% of p53+/ Exponentially growing cells on staining chamber slides were incubated in the complete medium in the presence of BrdU for 2 h. Cells were then processed for immunostaining using anti-BrdU antibody (see Materials and methods) Figure 2 Characterization of p53 in the cylin E-or control vector-transfected p53+/+, Waf17/7, and Waf1+/+ MEFs. (a) The pooled cyclin E-or control vector-transfectants described in the legend to Figure 1 (except for those derived from p537/7 MEFs) were metabolically labeled with 35 S-methionine/cystein (Materials and methods). After labeling, cell extracts were prepared and subjected to immunoprecipitation with Pab246 (speci®c to wild-type p53) and Pab240 (speci®c to mutant p53) (Yewdell et al., 1986 ; Gannon et al., 1990; Iggo et al., 1990) . The p537/7 MEFs expressing exogenously introduced temperature-sensitive p53 mutant (p53 val135 ) (designated as LTRcG) were included as a control. As previously shown, p53 val135 exists in both wild-type and mutant conformations at 378C (Martinez et al., 1991) . All of the p53+/+, Waf1+/+, and Waf17/7 cells transfected with either a cyclin E or a vector plasmid express p53 which is recognized only by Pab246, but not by Pab240. (b) It has been shown that Waf1 expression increases in a wild-type p53-dependent manner upon exposure to actinomycin D (Hickman et al., 1997) . p53+/+(Vec), p53+/+(CycE), Waf1+/+(Vec) and Waf1+/+(CycE) cells were treated with actinomycin D (30 nM) for 24 h. The parallel control cultures were untreated. The cell lysates were prepared, and subjected to immunoblot analysis using antiWaf1 polyclonal antibody (Ab-5, Calbiochem, CA, USA). All the cells examined show increased expression of Waf1 in response to actinomycin D, showing that these cells express p53 with a wild-type transactivation function +(Vec) cells are in G1 and the rest are in S, G2 and M phases of the cell cycle. Thus, in p53+/+(Vec) cells, the centrosome duplication cycle is coordinated with the DNA replication cycle. In p53+/+(CycE) cells, the number of cells with one centrosome greatly decreased (*17%) with a concomitant increase in the number of cells with two centrosomes (*77%). This is consistent with our previous ®ndings, in which cyclin E overexpression in Swiss 3T3 cells (containing wild-type p53) results in uncoupling of the initiation of centrosome duplication and DNA replication (Tarapore et al., submitted). In order to verify that those doublets detected by anti-g tubulin antibody represent duplicated centrosomes, cells were also immunostained with anti-a-and b-tubulin antibody cocktail after cold-treatment which destabilizes microtubules nucleated from centrosomes. Since a-and btubulins are the primary constituents of centrioles, a pair of centrioles in the core of the centrosome can be resolved as two dots by immunostaining of a-and btubulins at a high magni®cation. We found that each dot recognized by anti-g-tubulin antibody were resolved to doublets by anti-a-and b-tubulin antibodies (representative staining are shown in Figure 4 , panels d and d'), demonstrating that doublets detected by anti-g-tubulin antibody represented duplicated centrosomes. We also observed a minor, yet detectable increase in the number of cells containing 53 centrosomes (*6%) in p53+/+(CycE) compared with p53+/+(Vec) cells. Similar to p53+/+(CycE), there was a substantial decrease in the number of cells with one centrosome in p537/7(CycE) from 23 to 5%). However, instead of a corresponding increase in the number of cells with two centrosomes, a dramatic increase in the number of cells containing an abnormal number of centrosomes was observed. Thus, cyclin E overexpression appears to exacerbate abnormal ampli®cation of centrosomes associated with loss of p53.
Waf1 is involved in the coordination of the initiation of centrosome duplication and DNA replication
When Waf1+/+(Vec) cells were compared with Waf17/7(Vec) cells, we found that in Waf17/ 7(Vec) cells, there was a substantial decrease in the cell population with one centrosome (from *66 to *27%), and a concomitant increase in the cell population with two centrosomes (from *33% to *65%) ( Figure 5 ). When the cell cycle phase distributions of these cells (Table 1) are taken into consideration, this result indicates that Waf1 may play an important role in the coordination of the initiation of centrosome duplication and DNA replication. Importantly, Waf1+/+(CycE) cells showed a more prominent increase in the number of cells with two centrosomes (and a decrease in the number of cells with one centrosome) when compared with Waf17/ 7(Vec) cells. This suggests that endogenous Waf1 may at least partially function as a`checkpoint' to prevent premature initiation of centrosome duplication likely via inhibiting untimely activation of Cdk2-cyclin E. Upon cyclin E overexpression, the activity of Cdk2-cyclin E activation probably surpasses the level of endogenous Waf1, resulting in an increase in the rate of premature initiation of centrosome duplication. Indeed, we observed a further decrease in the number of cells with one centrosome in Waf17/7(CycE) cells (*6%) with a concomitant increase in the number of cells with two centrosomes (*84%).
In the absence of p53, regulation of both initiation of duplication at a proper time point and suppression of centrosome re-duplication are abrogated (Fukasawa et al., 1996) , leading to extensive centrosome hyperampli®cation as seen in p537/7(Vec) cells. Unlike p537/7(Vec) cells, Waf17/7(Vec) cells show only a small increase in the number of cells with hyperampli®ed centrosomes (*8%) when compared with Waf1+/+(Vec) cells (1.7%). This is also the case in Figure 3 Synergistic induction of centrosome hyperampli®cation by loss of p53 and cyclin E overexpression. Exponentially growing cells were processed for immuno-staining using rabbit anti-g-tubulin polyclonal antibody (Sigma). Antibody-antigen complexes were detected with rhodamine-conjugated goat anti-rabbit IgG, and examined under a¯uorescence microscope. For each cell line, at least 500 cells were scored. We also performed immunostainings using the antibody cocktail [anti-a-tubulin antibody (DM1A) and anti-b-tubulin antibodies (Tub.2.1 and DM1B) after CaCl 2 -cold treatment to destabilize microtubules prior to ®xation as described previously (Tarapore et al., submitted). This procedure allows identi®cation of intact centrosomes with a pair of centrioles, since the major components of centrioles are a-and b-tubulins. Thus, each signal (dot) detected by anti-g-tubulin antibody can be resolved into doublets of centrioles. By this method, we examined *100 cells for each cell line, and we obtained similar results. For a representative staining, see Figure 4 , panels d and d' Waf17/7(CycE) cells (*11%). These results indicate that Waf1 and Cdk2-cyclin may lie in the same regulatory pathway for the regulation of the centrosome duplication cycle, and that Waf1 primarily functions in establishing the correct timing of the initiation of centrosome duplication (and thus, the coordination of the initiation of centrosome duplication and DNA replication) through acting on Cdk2-cyclin E.
Synergistic induction of centrosome hyperamplification by functional inactivation/loss of p53 and cyclin E overexpression in rodent tumors
Cyclin E overexpression as well as mutational inactivation of p53 are frequently observed in a variety of tumors. Thus, it is possible that cyclin E overexpression and p53 mutations occur in the same tumors. The synergistic induction of centrosome hyperampli®cation by cyclin E overexpression and loss of p53 observed in the cultured cells led us to examine the tumors formed spontaneously in p537/7, p53+/7, and littermate p53+/+ mice for p53 status, cyclin E expression, and centrosome abnormalities. The tumors that developed in p53+/+ and p53+/7 mice were ®rst examined for p53 status by Southern blot [loss-of-heterozygosity (LOH)] analysis, immunoblot analysis, and a variety of functional assays (Venkatachalam et al., 1998) . Tumors formed in wild-type mice generally retained intact p53 alleles (Table 2a) . However, while some tumors that formed in p53+/7 mice retained wild-type p53 allele structure, some showed loss of the remaining p53 allele (Table 2b , indicated by LOH). In addition, p53+/7 tumors were also assessed for p53 functionality by induction of waf1 and mdm2 mRNA as well as apoptosis following radiation. We found that in all of the p53+/7 tumors, wild-type p53 functionality is maintained (data not shown, also see Venkatachalam et al., 1998) .
We also immunohistochemically examined the levels of Mdm2 expression in these tumors as described previously (Carroll et al., 1999) . Mdm2, through physical binding, inhibits p53 functions, including steric inhibition of its DNA binding activity (Momand et al., 1992; Oliner et al., 1993) and promotion of its Figure 4 Representative immunostainings of centrosomes in p53+/+ and p537/7 MEFs transfected with either cyclin E or a control vector. p53+/+(Vec), p53+/+(CycE), and p537/ 7(CycE) were immunostained with anti-g-tubulin antibody (a ± c) as described in the legend to Figure 3 . Cells were also counterstained with DAPI for visualization of nuclei (a' ± c'). Scale bars shown in a ± c indicate 10 mm. In order to examine whether each dot detected by anti-g-tubulin antibody, especially in cyclin E-overexpressing cells, represents an intact centrosome (containing a pair of centrioles), cells were also immunostained with anti-a-and btubulin antibody cocktail after cold-treatment (d, each pair of centrioles is indicated by an arrow) as described in the legend to Figure 3 . Scale bar, 5 mm Figure 5 Centrosomes in Waf17/7 and Waf1+/+ MEFs transfected with either a cyclin E plasmid or a control vector. Waf1+/ +(Vec), Waf1+/+(CycE), Waf17/7(Vec), and Waf17/7(CycE) cells were immunostained for centrosomes as described in the legend to Figure 3 . For each cell line, at least 500 cells were scored. We also performed immunostainings using the anti-a-and antib-tubulin antibody cocktail after CaCl 2 -cold treatment, and obtained similar results (data not shown) (c) Analysis of tumors developed in p537/7 mice C-1 7/7 + 7 7 C-2 7/7 + 7 7 C-3 7/7 + 7 7 C-4 7/7 + 7 7 C-5 7/7 + 7 7 C-6 7/7 + 7 7 C-7 7/7 + 7 + C-8 7/7 + 7 + C-9 7/7 ++ 7 7 C-10 7/7 ++ + + C-11 7/7 ++ + + C-12 7/7 ++ + + C-13 7/7 ++ + 7 C-14 7/7 ++ + 7 C-15 7/7 +++ + 7 C-16 7/7 +++ + 7 C-13 7/7 +++ + + a p53 status of the tumors that formed in p53+/+ and p53+/7 mice were assessed by Southern blot analysis (LOH test) and a variety of functional assays as described previously (Venkatachalam et al., 1998) . Some of the p53+/7 tumors were also assessed for p53 point mutations in the remaining wild-type allele by reverse transcriptase (RT) ± PCR based sequencing of the entire message. All sequenced p53 alleles were found negative for mutations (data not shown). All of the p53+/7 tumors presented are derived from p53+/7 mice. b Paran-embedded tumor samples were processed for immunostaining for g-tubulin (centrosomes) as described in Materials and methods. For evaluation of the degree of centrosome hyperampli®cation,`cut-o' values were set as follows:`+' if 510% of the tumor cells contain abnormal number of centrosomes (n53),`++' if 10 ± 30% of the tumor cells contain n53 centrosomes, and`+++' if 430% of the tumor cells contain n53 centrosomes. It should be noted that these evaluations of centrosome hyperampli®cation in tumor tissues underestimate the actual occurrence of centrosome hyperampli®cation in a given tumor, since some centrosomes are small and likely located outside of the section plane examined. Evaluation of the degrees of centrosome hyperampli®cation was done by two investigators independently.
c,d
Paran-embedded tumor samples were processed for co-immunostaining with anti-Mdm2 monoclonal antibody (SMP14, Santa Cruz, CA, USA) and anti-cyclin E polyclonal antibody (M-20, Santa Cruz, CA, USA). Evaluation of the immunostainings was done by two investigators independently degradation (Haupt et al., 1997; Kubbutat et al., 1997) . Moreover, Mdm2 overexpression is frequently observed in human as well as rodent tumors (reviewed in Momand and Zambetti, 1997) , especially those which retain wild-type p53 (Oliner et al., 1992) . In these tumor samples, we did not observe a signi®cant correlation between Mdm2 overexpression and retention of wild-type p53 (Table 2a ± c). The representative immunostainings of Mdm2 are shown in Figure 6a , panels a ± d. It should be noted that examination of these tumor samples by Northern blot and Southern blot analyses showed that not all Mdm2-positive tumors displayed signi®cant increases in the levels of Mdm2 mRNA or Mdm2 gene ampli®cation (Venkatachalam et al., 1998) , suggesting the possibility of post-translational stabilization of Mdm2 in some of the tumors (data not shown).
Tumor samples were then examined for centrosomes immunohistochemically using anti-g-tubulin antibody as described previously (Carroll et al., 1999) . The degrees of centrosome hyperampli®cation were evaluated as follows;`7' for no detectable ampli®cation, +' for apparently abnormal ampli®cation of centrosomes (n53) in 410% of the cells,`++' for n53 centrosomes in 10 ± 30% of the cells, and`+++' for n53 centrosomes in 430% of the cells. The representative immunostainings of centrosomes in dierent degrees of ampli®cation are shown in Figure  6b ). In p53+/+ tumors, four out of 11 tumors showed centrosome hyperampli®cation, and these tumors were all found to overexpress Mdm2 proteins (Table 2a) . This is consistent with our previous studies of human squamous cell carcinoma of head and neck, showing the strong correlation between Mdm2 overexpression and centrosome hyperampli®cation in the presence of wild-type p53 (Carroll et al., 1999) . Cyclin E overexpression, which was determined immunohistochemically [representative immunostainings are shown in Figure 6a (panels a' ± d')], was observed in several p53+/+ tumors (Table 2a) . Among these tumors, two samples (A-6 and A-7) showed cyclin E overexpression, but no immunohistochemically detectable levels of centrosome hyperampli®cation. Thus, cyclin E overexpression alone does not appear to induce centrosome hyperampli®cation at least to an immunohistochemically detectable level in tumors. Among p53+/7 tumors, 13 out of 20 tumors showed centrosome hyperampli®cation, and nine of these tumors with centrosome hyperampli®cation overexpressed Mdm2 (Table 2b) . Thus, Mdm2 overexpression may be in part necessary to induce immunohistochemically detectable levels of centrosome hyperampli®cation in the p53+/7 background. Seven tumors that formed in p53+/7 mice showed loss of the remaining p53 allele as detected by the LOH test, and these tumors except for one (B-21) showed centrosome hyperampli®cation. All of the tumors formed in p537/7 mice showed centrosome hyperampli®cation to various degrees. In these tumor samples, eight tumors overexpressed cyclin E (Table 2c ). When the extent of centrosome abnormalities were compared in these cyclin E-overexpressing tumors, it was evident that the higher degree of centrosome hyperampli®cation was correlated with double mutations of p53 inactivation and cyclin E overexpression. High degrees of centrosome hyperampli®cation in tumors formed in p53+/+ and p53+/7 mice also showed a correlation with cyclin E overexpression. Thus, like cultured cells, inactivation of p53 and cyclin E overexpression appear to synergistically induce centrosome hyperampli®cation in tumors.
Discussion
The centrosome duplication cycle is regulated in two ways: One ensures the proper timing to initiate centrosome duplication so that the initiation of centrosome duplication and DNA replication occur in a coordinated fashion. The other is to suppress reduplication of centrosomes once they are duplicated.
Involvement of p53 in these two types of regulation has been shown in cells derived from p53-null mice (Fukasawa et al., 1996) . In these cells, both types of regulation are abrogated, resulting in abnormal ampli®cation of centrosomes. It has been shown that the activation of Cdk2-cyclin E is a key event in the initiation of centrosome duplication (Matsumoto et al., 1999; Lacey et al., 1999; Hinchclie et al., 1999 ; Figure 6 Representative immunostainings of g-tubulin (centrosomes), Mdm2, and cyclin E in tumors developed in p53+/+, p53+/7, and p537/7 mice. (A) Paran-embedded tumor sections were co-immunostained with anti-Mdm2 monoclonal antibody (SMP14, Santa Cruz), and anti-cyclin E polyclonal antibody (M-20, Santa Cruz, CA, USA). Antigen-antibody complexes were visualized by FITC-conjugated goat anti-rabbit IgG antibody for cyclin E (panels a' ± d'), and by rhodamine-conjugated goat antimouse IgG antibody for Mdm2 (panels a ± d). Tissues were also stained with DAPI for visualization of nuclei (panels a'' ± d''). Panels a ± a'' are of the tumor C-4 (Table 2c) as an example of Mdm2 as`7' and cyclin E as`7'. Panels b ± b'' are of C-15 (Table 2c) as an example of Mdm2 as`7' and cyclin E as`+'. Panels c ± c'' are of C-7 (Table 2c) as an example of Mdm2 as`+' and cyclin E as 7'. Panels d ± d'' are of B-19 (Table 2b) as an example of Mdm2 as`+' and cyclin E as`+'. Magni®cation, 6400. (B) Paranembedded tumor sections were immunostained with anti-g-tubulin antibody (panels a ± d), and then stained with DAPI for visualization of nuclei (panels a' ± d'). Panels a and a' are stainings of the tumor A-6 (see Table 2a ) as an example of centrosomes evaluated as`7'. Panels b and b' are of C-17 (Table 2c) (Table 2c) respectively as examples of`+++'. It should be noted that not all of the centrosome(s) in each individual cell are immunostained, since centrosomes can be outside of the section plane examined. Magni®cation, 6600 Tarapore et al., 1999) . In the normal cell cycle, Cdk2-cyclin E is activated for a short period of time during late G1 phase, triggering initiation of both centrosome duplication and DNA replication. Initiation of centrosome duplication primarily depends on the activation of Cdk2-cyclin E, while initiation of DNA replication can only be triggered by Cdk2-cyclin E when other required steps are ful®lled (Stillman, 1996) . When cyclin E is overexpressed, Cdk2-cyclin E becomes constitutively activated, resulting in uncoupling of the centrosome duplication cycle and the DNA replication cycle; centrosome duplication initiates prior to S phase entry. Uncoupling of the centrosome duplication cycle and the DNA replication cycle results in a minor, but detectable increase in the frequency of centrosome abnormalities. Since cyclin E overexpression as well as p53 mutations are very frequent in a variety of cancers, we examined the eect of cyclin E overexpression and p53 mutations on centrosome homeostasis in cultured cells and tumors. There was a dramatic increase in the frequency of centrosome hyperampli®cation in p537/7 MEFs overexpressing cyclin E, when compared with p537/7 MEFs. This is further corroborated in tumors formed in p53+/+, p53+/7 and p537/7 mice. Occurrence of extensive centrosome hyperampli®cation strongly correlates with cyclin E overexpression and loss or mutational inactivation of p53. Thus, cyclin E overexpression appears to synergistically induce centrosome hyperampli®cation with p53 mutations. However, it should be noted that there are few cases that do not agree with our conclusion. For instance, some of p53+/7 tumors, which retain wild-type p53 allele and show no cyclin E or Mdm2 overexpression, display centrosome hyperampli®cation. In addition, one tumor (B-21, Table 2b) shows no centrosome hyperampli®cation despite loss of p53. These cases may suggest that multiple factors may be involved in centrosome homeostasis in addition to p53, Mdm2, and cyclin E. Indeed, examination of mice lacking GADD45, one of the targets of transcription activation function of p53, has recently revealed that centrosome hyperampli®cation and aneuploidy are frequent events in GADD457/7 mice Wang et al., 1999) , similar to p537/7 mice . It has also recently been found that BRCA1 tumor suppressor protein associates with centrosomes and is involved in the regulation of centrosome duplication (Hsu et al., 1998; Xu et al., 1999) . AIK1/STK15/BTAK, a tumor-associated kinase, has also been shown to associate with centrosomes and play a role in the regulation of centrosome duplication (Zhou et al., 1998; Tanaka et al., 1999) .
Our present study provides a potential molecular link between loss of p53 and activation of Cdk2-cyclin E in centrosome homeostasis. Waf1, a potent inhibitor of Cdk2-cyclin E, is one of the major proteins whose expression is transcriptionally activated by p53 (El-Deiry et al., 1993) . There is a substantial decrease in the number of cells with one centrosome (and concomitant increase in the number of cells with two centrosomes) in Waf17/7 cells and p537/7 cells when compared with wild-type cells. Together with the results from the cell cycle phase distribution patterns of these cells, it is clear that many Waf17/7 as well as p537/7 cells have initiated centrosome duplication prior to entry into S phase. This suggests that Waf1 may be involved in p53-mediated regulatory mechanisms that underlie the coordination of the initiation of centrosome duplication and DNA replication. We have observed that low levels of Waf1 are constitutively expressed in a p53-dependent manner (Horn et al., manuscript submitted). Thus, it is attractive to consider the possibility that Waf1, which is constitutively present at low levels in the presence of wild-type p53, may act as a checkpoint response protein to prevent premature initiation of centrosome duplication via inhibiting untimely activation of Cdk2-cyclin E. In support, Waf1+/+ cells overexpressing cyclin E show a further decrease in the number of cells with one centrosome compared with Waf17/7 cells. In these cells, the levels of Cdk2-cyclin E may surpass the levels of endogenous Waf1, resulting in the increased frequency of premature initiation of centrosome duplication. In fact, when cyclin E is overexpressed in Waf17/7 cells, the number of cells with one centrosome further decreases to almost negligible levels.
Cyclin E overexpression or loss of Waf1 results in only a small increase in the frequency of centrosome hyperampli®cation, which is considerably lower than that seen in p537/7 cells. The role of Waf1 in the centrosome duplication cycle is primarily detected in the coordination of the initiation of centrosome duplication and DNA replication. Currently we do not know whether the centrosome hyperampli®cation observed in Waf17/7 cells or cyclin E-overexpressing cells is attributed to abrogation of suppression of centrosome re-duplication or failure to undergo cytokinesis. The latter possibility is indirectly supported by the recent reports showing that Waf1 functions in the regulation of the G2/M transition (Niculescu et al., 1998) .
Chromosome instability plays an important role in tumor progression, presumably through promoting the rate of karyotypic alterations necessary for establishing the malignant phenotypes (Nowell, 1976) . Centrosome hyperampli®cation, one of the major causes in chromosome instability associated with p53 mutations, is exacerbated by concurrent cyclin E overexpression. Recently, Spruck et al. (1999) have shown that constitutive overexpression of cyclin E in cells results in chromosome instability. Our study extends these observations, in which cyclin E overexpression destabilizes the genome at least in part by promoting abnormal ampli®cation of centrosomes. It is of great importance to further elucidate the molecular link between Cdk2-cyclin E activation and p53 mutations as well as the role of Waf1 in the control of the centrosome duplication cycle. In addition, examination of centrosome hyperampli®cation and chromosome instability in human cancers in association with cyclin E overexpression and p53 mutations will provide critical information to understand the mechanisms of chromosome instability in human cancers. These studies are currently underway in our laboratory.
Materials and methods

Cells
Waf17/7 and Waf1+/+ MEFs (generous gifts from Dr P Leder, Harvard Medical School, MA, USA), as well as p537/7 and p53+/+ MEFs were maintained in complete medium [Dulbecco Modi®ed Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 mg/ml)], and grown in an atmosphere containing 10% CO 2 .
p53 alteration has been shown to be a common event in the immortalization of primary MEFs (Harvey and Rittling and Denhardt, 1992) . However, it has been shown that p53 mutations arise and are preferentially selected during the immortalization process using the 3T12, but not the 3T3 protocol (Rittling and Denhardt, 1992) . Thus, to establish the immortalized p53+/+ and Waf1+/+ MEFs, while minimizing the occurrence of p53 alterations, cells were cultured according to the 3T3 protocol (Todaro and Green, 1963) . During establishment and maintenance of cells, we carefully monitored cells so that they were not con¯uent in culture dishes.
Immunoblot analysis
Cells were washed twice in phosphate buered saline (PBS) and lysed in SDS-NP-40 lysis buer [1% SDS, 1% Nonidet P-40 (NP-40), 50 mM Tris (pH 8.0), 150 mM NaCl, 4 mM Pefabloc SC (Boehringer Mannheim), 2 mg/ml leupeptin, 2 mg/ml aprotinin]. The lysates were brie¯y sonicated, boiled for 5 min, and then cleared by a 10 min centrifugation at 20 000 g at 48C. The supernatant was further denatured at 958C for 5 min in sample buer [2% SDS, 10% glycerol, 60 mM Tris (pH 6.8), 5% b-mercaptoethanol, 0.01% bromophenol blue]. Samples were resolved by SDS ± PAGE, and fractionated proteins were transferred to Immobilon (Milipore) sheets. The blots were incubated in blocking buer [5% wt/vol) nonfat dry milk in Tris-buered saline+0.2% Tween 20 (TBS-T)] for 1 h at room temperature and then primary antibody for 2 h at room temperature. The blots were then rinsed in TBS-T and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots were rinsed in TBS-T, and the antibody-antigen complex was visualized by ECL chemiluminescence (Amersham) according to the manufacturer's instructions.
Indirect immunofluorescence
Cells grown on slides were washed twice with PBS and ®xed with 10% formalin for 20 min at room temperature. The cells were then washed with PBS and permeabilized with 1% NP-40 in PBS for 5 min at room temperature. Cells were ®rst incubated with blocking solution (10% normal goat serum in PBS) for 1 h and then probed with anti-g-tubulin polyclonal antibody (6, 7) for 1 h. The antibody-antigen complexes were detected with FITC-conjugated goat anti-rabbit IgG antibody (Boehringer Mannheim) by incubation for 1 h at room temperature. The samples were washed three times with TBS after each incubation, and then counterstained with 4',6-diamidino 2-phenylindole (DAPI) DNA dye.
For the paran-embedded tumor tissue samples, the 5-mmthick sections cut from the paran block were deparanized and processed for immunostaining as described (Harlow and Lane, 1988; Carroll et al., 1999) .
Immunoprecipitation
Cells growing at a subcon¯uent density were washed three times with methionine (met) and cysteine (cys)-free DMEM and incubated in met, cys-free DMEM supplemented with 75 mCi/ml [ 35 S]-met and cys (trans 35 S-label, ICN Biomedical) with 5% dialyzed FBS. After 3 h metabolic labeling, cells were washed with PBS three times, and then lysed in NP-40 lysis buer (1% NP-40, 150 mM NaCl, 50 mM Tris (pH 8.0), 5 mM EDTA, 4 mM Pefabloc SC, 2 mg/ml leupeptin, 2 mg/ml aprotinin). The lysates were cleared by centrifugation for 15 min at 20 000 g at 48C. The lysates containing 200 mg of total proteins were immunoprecipitated with the anti-p53 monoclonal antibodies, Pab246 and Pab240 (Santa Cruz, CA, USA). The antibody-antigen complexes were collected with protein G-agarose, and washed four times with NP-40 lysis buer. The immunocomplexes were then denatured in sample buer at 958C for 5 min and resolved by 10% SDS ± PAGE.
5-bromo-2'-deoxyuridine (BrdU) incorporation assay
The entire procedure was performed using a cell proliferation assay kit (Amersham) as instructed by the supplier. Brie¯y, the exponentially proliferating cells were incubated in the labeling medium containing BrdU and 5-¯uoro-2'-deoxyuridine (10 : 1 ratio) for 2 h. Cells were then washed with PBS, and ®xed with acetic acid/ethanol. After blocking with 3% BSA in PBS-T (PBS+0.1% Tween 20), cells were incubated with anti-BrdU monoclonal antibody, then with FITCconjugated goat anti-mouse IgG2a, and examined under ā uorescence microscope.
Flow cytometry
Exponentially growing cells (*2610 6 ) were collected by trypsinization. The cells were washed once with PBS, then ®xed in 70% ethanol for 30 min. Fixed cells were brie¯y pelleted, resuspended in PBS, and treated with RNase A (100 mg/ml) for 30 min at 378C. Propidium iodide (10 mg/ml) was added to the cell suspension prior to the analysis.
